Aptamer Group PLC
LSE:APTA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Aptamer Group PLC
Change in Working Capital
Aptamer Group PLC
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Aptamer Group PLC
LSE:APTA
|
Change in Working Capital
£27k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Change in Working Capital
-£9.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Change in Working Capital
-$14.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-83%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Change in Working Capital
-£52.3m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-9%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Change in Working Capital
£8.4m
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Niox Group PLC
LSE:NIOX
|
Change in Working Capital
-£700k
|
CAGR 3-Years
60%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
Aptamer Group PLC
Glance View
Aptamer Group Plc operates as a biotechnology company. The firm provides custom Optimer selection and development services. The firm provides transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. The firm has developed a proprietary platform technology that drives three distinct businesses: Aptamer solutions for custom Optimer development, Aptamer diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer therapeutics for the development of Optimer-based therapeutics. Optimer can act as agonists, antagonists or cell-type-specific targeting moieties for the delivery of therapeutic agents to target cells and tissues in the treatment of disease.
See Also
What is Aptamer Group PLC's Change in Working Capital?
Change in Working Capital
27k
GBP
Based on the financial report for Jun 30, 2025, Aptamer Group PLC's Change in Working Capital amounts to 27k GBP.
What is Aptamer Group PLC's Change in Working Capital growth rate?
Change in Working Capital CAGR 1Y
-94%
Over the last year, the Change in Working Capital growth was -94%.
